Satisfactory safety and immunogenicity of MSP3 malaria vaccine candidate in Tanzanian children aged 12-24 months.
Lusingu JP, Gesase S, Msham S, Francis F, Lemnge M, Seth M, Sembuche S, Rutta A, Minja D, Segeja MD, Bosomprah S, Cousens S, Noor R, Chilengi R, Druilhe P.
Lusingu JP, et al. Among authors: francis f.
Malar J. 2009 Jul 17;8:163. doi: 10.1186/1475-2875-8-163.
Malar J. 2009.
PMID: 19607731
Free PMC article.
Clinical Trial.